Ono Pharmaceutical

Ono to Acquire Deciphera for $2.4 Billion

Japan’s Ono Pharmaceutical agreed to acquire US cancer-therapy company Deciphera Pharmaceuticals for approximately $2.4 billion. Deciphera focuses on innovative cancer therapeutics, and specializes in kinase biology.

News

Merck Settles Keytruda Patent Disputes

News

Merck, Ono To Jointly Develop Oral Multiple Sclerosis Drug, Cancer Immunotherapy

Top-Feature

BIO Deutschland e.V.

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.